Moderna-Merck Skin Cancer Treatment Shows Long-Term Benefits

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...

Personalized skin cancer treatment shows success in treating melanoma

New personalized skin cancer treatment shows success in preventing return of high-risk melanoma - Patients with severe ...

New melanoma vaccine shows promise in preventing skin cancer return

Moderna and Merck's melanoma vaccine, combined with Keytruda, could halve cancer recurrence risk, marking a breakthrough in ...
CURE

How A Cancer Vaccine and Keytruda Work to Treat Patients With Melanoma

Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer vaccine, when combined with the immunotherapy Keytruda (pembrolizumab), has been associated with a 49% ...

Moderna–Merck Cancer Vaccine Shows Durable Benefit At 5 Years In High-Risk Melanoma

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or ...
NBC New York

Moderna and Merck Cancer Vaccine Used With Keytruda Reduces Risk of Deadly Skin Cancer Spreading

Moderna and Merck's experimental cancer vaccine, used in combination with Merck's Keytruda, reduced the risk of the most deadly form of skin cancer spreading to other parts of the body in a clinical ...
BioSpace

Moderna, Merck Show Long-Term Survival for mRNA-Keytruda Combo

The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...
Morningstar

PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer

TOKYO, Oct. 22, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) accepted for ...